Xenon Pharmaceuticals
XENE
315 hedge funds and large institutions have $6.1B invested in Xenon Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 125 increasing their positions, 87 reducing their positions, and 22 closing their positions.
862% more call options, than puts
Call options by funds: $67.5M | Put options by funds: $7.01M
127% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 22
44% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 87
9% more funds holding
Funds holding: 290 → 315 (+25)
5% more capital invested
Capital invested by funds: $5.8B → $6.1B (+$295M)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
15.88% less ownership
Funds ownership: 120.48% → 104.6% (-16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$107M |
| 2 |
BlackRock
New York
|
+$105M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$67.5M |
| 4 |
Two Sigma Investments
New York
|
+$57.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$46.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$189M |
| 2 |
Holocene Advisors
New York
|
-$88.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$69.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$65M |
| 5 |
Jennison Associates
New York
|
-$61.7M |
XENE Hedge Fund Activity: Q2 2026 in Review
315 of the 8,299 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2026, worth a combined $6.1B — up 5.1% from $5.8B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new XENE positions and 22 closed out — a net gain of 28 holders — while 125 added to existing stakes and 87 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $107M. The largest seller was Wellington Management Group, cutting an estimated $189M.
- 315 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2026, up from 290 in Q1 2026.
- Funds reported $6.1B of Xenon Pharmaceuticals stock for Q2 2026, up 5.1% quarter-over-quarter.
- 50 funds opened new Xenon Pharmaceuticals positions in Q2 2026 and 22 closed out, a net change of +28 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2026 was T. Rowe Price Associates, an estimated $107M added.
- The largest Xenon Pharmaceuticals seller in Q2 2026 was Wellington Management Group, an estimated $189M sold.
Based on aggregated 13F filings for Q2 2026.